Blake Insomnia Therapeutics Announces Appointment Of Morten Albrechtsen To Its Board Of Directors
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is pleased to announce the appointment of Morten Albrechtsen, to its Board of Directors.
Morten Albrechtsen MD, BBA is a seasoned entrepreneur and investor with a strong medical, commercial and financial background. He has great depth within most therapeutic areas and with both drugs and devices. Mr. Albrechtsen’s development expertise includes all stages pre-clinical, clinical and post-market development, and most disciplines. He has international commercialization expertise and has helped with sales through partners, affiliates and direct to patients, hospitals and direct to end-users.
Morten Albrechtsen is an experienced business leader with a strong medical, commercial and financial background. After holding executive positions at several large pharmaceutical companies, including Boehringer Ingelheim and Nycomed (later acquired by Takeda Pharmaceutical), he founded ENKAM Pharmaceuticals in 2001. Since then, he has divided his time between consultancy work and executive roles, primarily at companies 2–4 years prior to cash-generating transactions. In addition to his role at Blake, Morten serves as co-founder and CEO at radiotherapy specialists Nanovi, part-time CEO at a number of pharma-related startups and executive chairman at the clinical CRO NORMA. Known as an expert deal-maker, Morten has extensive experience with turnarounds, spinoffs, business development, licensing and corporate deals, including M&A and financing.
“We are very happy to have Mr. Albrechtsen join our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Mr. Albrechtsen’s experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules and he is a strong asset to our team.” Morten will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 news@blakeinsomnia.com